Welcome to our dedicated page for Springworks Therapeutics SEC filings (Ticker: SWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to historical U.S. Securities and Exchange Commission (SEC) filings associated with SpringWorks Therapeutics, Inc., which previously traded on Nasdaq under the ticker SWTX. These documents trace the company’s evolution from a standalone commercial-stage biopharmaceutical issuer to its acquisition by Merck KGaA, Darmstadt, Germany and subsequent deregistration as a public company.
For investors analyzing SWTX, key filings include current reports on Form 8-K describing material events such as the April 27, 2025 Agreement and Plan of Merger and the July 1, 2025 completion of the merger in which a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany merged with and into SpringWorks. The July 1, 2025 Form 8-K explains that SpringWorks became a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany, that each share of common stock was converted into the right to receive cash consideration, and that a change in control occurred.
Listing and registration changes are documented in a Form 25 filed by The Nasdaq Stock Market LLC on July 1, 2025, which notifies the SEC of the removal of SpringWorks common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. A subsequent Form 15 filed by SpringWorks on July 11, 2025 certifies the termination of registration of its common stock under Section 12(g) and the suspension of its duty to file reports under Sections 13 and 15(d), noting one holder of record as of the certification date.
Earlier periodic and transactional filings, such as annual and quarterly reports and proxy materials, provide additional detail on SpringWorks’ business, including the development and commercialization of OGSIVEO (nirogacestat) for desmoid tumors and GOMEKLI (mirdametinib) for NF1-PN, as well as its pipeline of targeted therapy product candidates. Together, these filings offer a regulatory history of SWTX, from its time as a listed issuer through its acquisition and delisting.
On Stock Titan, users can view these filings in sequence and use AI-powered tools to summarize lengthy documents, highlight key terms such as merger consideration, delisting notices, or risk factor language, and quickly locate references to specific products, clinical programs or corporate actions in the SpringWorks Therapeutics filing record.
SpringWorks Therapeutics, Inc. (SWTX) has filed a Form 25 with the U.S. Securities and Exchange Commission. Nasdaq Stock Market LLC, acting as the filer, is removing the company’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The form certifies that Nasdaq has complied with the procedural requirements of 17 CFR 240.12d2-2(b), which allows an exchange to strike a security from listing, and notes that the issuer has likewise satisfied the conditions for voluntary withdrawal under 17 CFR 240.12d2-2(c) if applicable.
The document contains no explanation for the delisting, nor does it provide financial statements or indicate any concurrent corporate action such as a merger, acquisition, or transfer to another trading venue. The filing was signed on 1 July 2025 by Tara Petta, AVP, on behalf of Nasdaq Stock Market LLC. Once effective—generally 10 days after filing—the company’s common stock will no longer be traded on Nasdaq, and its Section 12(b) registration will be withdrawn.
SpringWorks Therapeutics (Nasdaq:SWTX) filed an 8-K reporting the June 26, 2025 special meeting results regarding its proposed acquisition by Merck KGaA, Darmstadt, Germany.
- Quorum: 59.0 million shares (78.31% of outstanding) were represented.
- Merger Agreement adopted with 58.90 million FOR, 0.09 million AGAINST, 0.01 million ABSTAIN (99.85% support).
- Because Proposal 1 passed decisively, the Adjournment Proposal was not needed.
- Advisory compensation for named executives linked to the merger also passed (92% support).
The shareholder vote removes a key closing condition; the transaction now awaits customary regulatory and other approvals. The filing reiterates forward-looking-statement caveats and outlines risks such as termination rights, regulatory delays and litigation.
FAQ
What is the current stock price of Springworks Therapeutics (SWTX)?
What is the market cap of Springworks Therapeutics (SWTX)?
